Gustavo Cancela e Penna Alterações moleculares na tumorigênese ...

Fagin J, Mitsiades N. Molecular pathology of thyroid cancer:diagnostic and
clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22:
955-969
Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Loda M, Vella V,
Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R. BRAF (V¨600E)
Mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer
2008; 15: 191-205
Fusco A, Santoro M. 20 Years of RET/PTC in thyroid cancer: clinico-
pathological correlations. Arq Bras Endocrinol Metab 2007; 51: 731-735
Glover T, Berger C, Coyle J, Echo B. DNA polymerase a inhibition by
aphidicolin induces gaps and breaks at common fragile sites in human
chromosomes. Hum Genet 1984; 67:136-142
Glover T. Common fragile sites. Cancer Letters 2006; 232: 4-12
Guler G, Uner A, Guler N, Han S, Iliopoulos D, Hauck W, McCue P, Huebner K.
The fragile genes FHIT and WWOX are inactivated coordinately in
invasive breast carcinoma. Cancer 2004; 100: 1605-1614
Iliopoulos D, Guler G, Han S, Druck T, Ottey M, McCorkell K, Huebner K. Roles
of FHIT and WWOX fragile genes in cancer. Cancer Letters 2006; 232:
27-36
Jo S, Li S, Song J, Kwon K, Lee J, Rha S, Lee H, Sul J, Kweon G, Ro H, Kim J,
Shong M. Influence of the BRAF V600E mutation on expression of
39